keyword
https://read.qxmd.com/read/38630364/sirtuins-and-cellular-senescence-in-patients-with-idiopathic-pulmonary-fibrosis-and-systemic-autoimmune-disorders
#1
REVIEW
Vito D'Agnano, Domenica Francesca Mariniello, Raffaella Pagliaro, Mehrdad Savabi Far, Angela Schiattarella, Filippo Scialò, Giulia Stella, Maria Gabriella Matera, Mario Cazzola, Andrea Bianco, Fabio Perrotta
The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several degenerative diseases have recently been linked to aberrant sirtuin expression and activity because of the involvement of sirtuins in maintaining cell longevity and their putative antiaging function. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis associated with systemic autoimmune disorders are severe diseases characterized by premature and accelerated exhaustion and failure of alveolar type II cells combined with aberrant activation of fibroblast proliferative pathways leading to dramatic destruction of lung architecture...
April 17, 2024: Drugs
https://read.qxmd.com/read/38497368/the-pharmacological-management-of-asthma-in-adults-2023-update
#2
REVIEW
Maria Gabriella Matera, Barbara Rinaldi, Rosa Annibale, Vito De Novellis, Mario Cazzola
INTRODUCTION: The pharmacotherapy of asthma is a dynamic process that changes as our knowledge of the underlying pathophysiology and treatment of this disease continues to evolve. This implies the need for continuous revision of the recommendations of asthma guidelines and strategies. AREAS COVERED: This review summarizes the latest key practical information on the pharmacological management of asthma in adults. We provide the background to the 2023 update of the GINA strategy report, focusing on changes and discussing areas of uncertainty...
March 20, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38431058/impact-of-biologics-on-lung-hyperinflation-in-patients-with-severe-asthma
#3
JOURNAL ARTICLE
Mauro Maniscalco, Claudio Candia, Cecilia Calabrese, Maria D'Amato, Maria Gabriella Matera, Antonio Molino, Mario Cazzola
BACKGROUND: In asthma, inflammation affects both the proximal and distal airways and can cause significant hyperinflation, which is thought to be a major cause of dyspnea. METHODS: This is a retrospective observational study evaluating the effect of three months of treatment with different biologic drugs (benralizumab, dupilumab and omalizumab) on pulmonary hyperinflation in a cohort of patients with severe asthma already receiving regular triple inhaled therapy...
February 29, 2024: Respiratory Medicine
https://read.qxmd.com/read/38419021/the-effect-of-combining-an-inhaled-corticosteroid-and-a-long-acting-muscarinic-antagonist-on-human-airway-epithelial-cells-in-vitro
#4
JOURNAL ARTICLE
Maria Gabriella Matera, Barbara Rinaldi, Cecilia Calabrese, Carmela Belardo, Luigino Calzetta, Mario Cazzola, Clive Page
BACKGROUND: Airway epithelial cells (AECs) are a major component of local airway immune responses. Direct effects of type 2 cytokines on AECs are implicated in type 2 asthma, which is driven by epithelial-derived cytokines and leads to airway obstruction. However, evidence suggests that restoring epithelial health may attenuate asthmatic features. METHODS: We investigated the effects of passive sensitisation on IL-5, NF-κB, HDAC-2, ACh, and ChAT in human bronchial epithelial cells (HBEpCs) and the effects of fluticasone furoate (FF) and umeclidinium (UME) alone and in combination on these responses...
February 28, 2024: Respiratory Research
https://read.qxmd.com/read/38398384/the-impact-of-thermal-water-in-asthma-and-copd-a-systematic-review-according-to-the-prisma-statement
#5
REVIEW
Luigino Calzetta, Nicola Di Daniele, Alfredo Chetta, Marco Vitale, Shima Gholamalishahi, Mario Cazzola, Paola Rogliani
BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) are global health challenges leading to substantial morbidity and mortality. While existing guidelines emphasize evidence-based treatments, the potential therapeutic role of thermal water (TW) inhalation remains under-investigated. METHODS: This systematic review followed PRISMA-P guidelines and sought to evaluate the impact of TW in asthma and COPD. A thorough literature search, performed up to May 2023, encompassed in vitro, in vivo, randomized controlled trial (RCT), non-RCT, and observational studies...
February 14, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38321329/cardiovascular-events-with-the-use-of-long-acting-muscarinic-receptor-antagonists-an-analysis-of-the-faers-database-2020-2023
#6
JOURNAL ARTICLE
Maria Gabriella Matera, Luigino Calzetta, Paola Rogliani, Nicola Hanania, Mario Cazzola
PURPOSE: This study aimed to examine reports of cardiovascular adverse events (CV AEs) observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and umeclidinium alone or in combination with a LABA and, in the context of triple therapy, with the addition of an ICS, and submitted to the food and drug administration adverse event reporting system (FAERS). METHODS: A retrospective disproportionality analysis was conducted utilizing CV AE reports submitted to the FAERS from January 2020 to 30 September 2023...
February 6, 2024: Lung
https://read.qxmd.com/read/38294705/biologics-for-asthma-and-risk-of-pneumonia
#7
JOURNAL ARTICLE
Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, Paola Rogliani, Mario Cazzola
OBJECTIVE: Modification of the immune system with biologics raises theoretical concerns about the risk of infections but it is still unclear whether currently routinely used biologics in severe asthma may facilitate the development of pneumonia. Therefore, we aimed to determine whether omalizumab, mepolizumab, benralizumab, and dupilumab are associated with pneumonia in a real-world setting. METHODS: A retrospective disproportionality analysis was performed using adverse event (AE) reports submitted to FAERS from January 2020 to September 30, 2023...
January 31, 2024: Journal of Asthma
https://read.qxmd.com/read/38249092/exercise-induced-asthma-managing-respiratory-issues-in-athletes
#8
REVIEW
Josuel Ora, Patrizia De Marco, Mariachiara Gabriele, Mario Cazzola, Paola Rogliani
Asthma is a complex respiratory condition characterized by chronic airway inflammation and variable expiratory airflow limitation, affecting millions globally. Among athletes, particularly those competing at elite levels, the prevalence of respiratory conditions is notably heightened, varying between 20% and 70% across specific sports. Exercise-induced bronchoconstriction (EIB) is a common issue among athletes, impacting their performance and well-being. The prevalence rates vary based on the sport, training environment, and genetics...
January 3, 2024: Journal of Functional Morphology and Kinesiology
https://read.qxmd.com/read/38153774/introduction-to-a-review-series-on-myelodysplastic-syndromes-in-the-age-of-genomic-medicine
#9
EDITORIAL
Mario Cazzola
No abstract text is available yet for this article.
December 28, 2023: Blood
https://read.qxmd.com/read/37958258/hyperglycaemia-and-chronic-obstructive-pulmonary-disease
#10
REVIEW
Mario Cazzola, Paola Rogliani, Josuel Ora, Luigino Calzetta, Davide Lauro, Maria Gabriella Matera
Chronic obstructive pulmonary disease (COPD) may coexist with type 2 diabetes mellitus (T2DM). Patients with COPD have an increased risk of developing T2DM compared with a control but, on the other side, hyperglycaemia and DM have been associated with reduced predicted levels of lung function. The mechanistic relationships between these two diseases are complicated, multifaceted, and little understood, yet they can impact treatment strategy. The potential risks and benefits for patients with T2DM treated with pulmonary drugs and the potential pulmonary risks and benefits for patients with COPD when taking antidiabetic drugs should always be considered...
November 1, 2023: Diagnostics
https://read.qxmd.com/read/37955136/advances-in-adrenergic-receptors-for-the-treatment-of-chronic-obstructive-pulmonary-disease-2023-update
#11
REVIEW
Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Paola Rogliani, Mario Cazzola
INTRODUCTION: Strong scientific evidence and large experience support the use of β2 -agonists for the symptomatic alleviation of COPD. Therefore, there is considerable effort in discovering highly potent and selective β2 -agonists. AREAS COVERED: Recent research on novel β2 -agonists for the treatment of COPD. A detailed literature search was performed in two major databases (PubMed/MEDLINE and Scopus) up to September 2023." EXPERT OPINION: Compounds that preferentially activate a Gs - or β-arrestin-mediated signaling pathway via β- adrenoceptors (ARs) are more innovative...
2023: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/37939379/pharmacological-interpretation-of-the-efficacy-of-ensifentrine-in-copd-insights-from-enhance-trials
#12
JOURNAL ARTICLE
Luigino Calzetta, Mario Cazzola, Paola Rogliani
No abstract text is available yet for this article.
November 8, 2023: American Journal of Respiratory and Critical Care Medicine
https://read.qxmd.com/read/37879449/is-it-preferable-to-administer-a-bronchodilator-once-or-twice-daily-when-treating-copd
#13
REVIEW
Maria Gabriella Matera, Barbara Rinaldi, Concetta Ambrosio, Mario Cazzola
Night-time and early morning symptoms are common and uncomfortable in many patients with COPD, and likely to negatively influence their long-term outcomes. However, it is still debated whether it is preferable to administer long-acting bronchodilators once- or twice-daily to symptomatic COPD patients. The functional link between circadian rhythms of autonomic tone and airway calibre explains why the timing of administration of bronchodilators in chronic airway diseases can induce different effects when taken at different biological (circadian) times...
October 23, 2023: Respiratory Medicine
https://read.qxmd.com/read/37859567/use-of-human-airway-smooth-muscle-in-vitro-and-ex-vivo-to-investigate-drugs-for-the-treatment-of-chronic-obstructive-respiratory-disorders
#14
REVIEW
Luigino Calzetta, Clive Page, Maria Gabriella Matera, Mario Cazzola, Paola Rogliani
Isolated airway smooth muscle has been extensively investigated since 1840 to understand the pharmacology of airway diseases. There has often been poor predictability from murine experiments to drugs evaluated in patients with asthma or chronic obstructive pulmonary disease (COPD). However, the use of isolated human airways represents a sensible strategy to optimise the development of innovative molecules for the treatment of respiratory diseases. This review aims to provide updated evidence on the current uses of isolated human airways in validated in vitro methods to investigate drugs in development for the treatment of chronic obstructive respiratory disorders...
March 2024: British Journal of Pharmacology
https://read.qxmd.com/read/37841747/clinically-important-deterioration-cid-and-ageing-in-copd-a-systematic-review-and-meta-regression-analysis-according-to-prisma-statement
#15
REVIEW
Gian Marco Manzetti, Josuel Ora, Arianna Sepiacci, Mario Cazzola, Paola Rogliani, Luigino Calzetta
PURPOSE: Clinically important deterioration (CID) is a composite endpoint developed to quantify the impact of pharmacological treatment in clinical trials for Chronic Obstructive Pulmonary Disease (COPD), also showing a prognostic value. CID is defined as any of the following condition: forced expiratory volume in 1 s decrease ≥100 mL from baseline, and/or St. George's Respiratory Questionnaire total score increase ≥4-unit from baseline, and/or the occurrence of a moderate-to-severe exacerbation of COPD...
2023: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/37779474/what-role-will-ensifentrine-play-in-the-future-treatment-of-chronic-obstructive-pulmonary-disease-patients-implications-from-recent-clinical-trials
#16
REVIEW
Mario Cazzola, Clive Page, Luigino Calzetta, Dave Singh, Paola Rogliani, Maria Gabriella Matera
Data from the phase III ENHANCE clinical trials provide compelling evidence that ensifentrine, an inhaled 'bifunctional' dual phosphodiesterase 3/4 inhibitor, can provide additional benefit to existing treatments in patients with chronic obstructive pulmonary disease and represents a 'first-in-class' drug having bifunctional bronchodilator and anti-inflammatory activity in a single molecule. Ensifentrine, generally well tolerated, can provide additional bronchodilation when added to muscarinic receptor antagonists or β2 -agonists and reduce the exacerbation risk...
October 2, 2023: Immunotherapy
https://read.qxmd.com/read/37752217/lung-microbiome-as-a-treatable-trait-in-chronic-respiratory-disorders
#17
REVIEW
Filippo Scialò, Maria Vitale, Vito D'Agnano, Domenica Francesca Mariniello, Fabio Perrotta, Alice Castaldo, Susan F M Campbell, Lucio Pastore, Mario Cazzola, Andrea Bianco
Once thought to be a sterile environment, it is now established that lungs are populated by various microorganisms that participate in maintaining lung function and play an important role in shaping lung immune surveillance. Although our comprehension of the molecular and metabolic interactions between microbes and lung cells is still in its infancy, any event causing a persistent qualitative or quantitative variation in the composition of lung microbiome, termed "dysbiosis", has been virtually associated with many respiratory diseases...
September 26, 2023: Lung
https://read.qxmd.com/read/37740909/a-comprehensive-overview-of-investigational-elastase-inhibitors-for-the-treatment-of-acute-respiratory-distress-syndrome
#18
REVIEW
Maria Gabriella Matera, Paola Rogliani, Josuel Ora, Luigino Calzetta, Mario Cazzola
INTRODUCTION: Excessive activity of neutrophil elastase (NE), the main enzyme present in azurophil granules in the neutrophil cytoplasm, may cause tissue injury and remodeling in various lung diseases, including acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), in which it is crucial to the immune response and inflammatory process. Consequently, NE is a possible target for therapeutic intervention in ALI/ARDS. AREAS COVERED: The protective effects of several NE inhibitors in attenuating ALI/ARDS in several models of lung injury are described...
September 23, 2023: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/37715502/strategies-for-overcoming-the-biological-barriers-associated-with-the-administration-of-inhaled-monoclonal-antibodies-for-lung-diseases
#19
REVIEW
Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi, Mario Cazzola, Paola Rogliani
INTRODUCTION: Monoclonal antibodies (mAbs) should be administered by inhalation rather than parenterally to improve their efficiency in lung diseases. However, the pulmonary administration of mAbs in terms of aerosol technology and the formulation for inhalation is difficult. AREAS COVERED: The feasible or suitable strategies for overcoming the barriers associated with administering mAbs are described. EXPERT OPINION: Providing mAbs via inhalation to individuals with lung disorders is still difficult...
September 16, 2023: Expert Opinion on Drug Delivery
https://read.qxmd.com/read/37705673/can-treatable-traits-be-the-approach-to-addressing-the-complexity-and-heterogeneity-of-copd
#20
JOURNAL ARTICLE
Mario Cazzola, Paola Rogliani, Francesco Blasi
The complexity of COPD implies the need to identify groups of patients with similar clinical characteristics and prognosis or treatment requirements. This is why much attention has been paid to identifying the different clinical phenotypes by investigating the clinical expression of the disease, and endotypes by studying the biological networks that enable and limit reactions. However, this approach is complicated because one endotype gives rise to one or more clinical characteristics, and clinical phenotypes can be derived from several endotypes...
2023: International Journal of Chronic Obstructive Pulmonary Disease
keyword
keyword
92322
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.